Results 141 to 150 of about 108,215 (260)

A Rare Case of Primary Thyroid Lymphoma. [PDF]

Cureus
Zitser D, Frugoli A, Kong L, Nikoomanesh T, Singh N.   +4 more
europepmc   +1 more source

Diffuse Large B-Cell Lymphoma in 2016

Journal of Clinical and Experimental Hematopathology, 2016
openaire   +3 more sources

Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A nationwide population‐based study

British Journal of Haematology, EarlyView.
Real‐world nationwide data in B‐cell malignancies reveal a markedly increased 1‐year incidence of hospitalized atrial fibrillation with ibrutinib compared with second‐generation Bruton's tyrosine kinase inhibitors and venetoclax, arguing for closer cardiac surveillance.
Yoann Zelmat, Loic Ysebaert, Paul Gautier, Agnes Sommet, Margaux Lafaurie, Fabien Despas   +5 more
wiley   +1 more source

The Sanctuary Within: Development of CD20+ CNS Lymphoma Despite Peripheral B-Cell Depletion by Rituximab in a Multiple Sclerosis Patient. [PDF]

Case Rep Neurol Med
Harirchian MH, Mohammadianinejad SE, Bayati A, Soleimani V, Sarvestani Z, Kaeedi M, Havadaragh SH.   +6 more
europepmc   +1 more source

Effects of chronic lymphocytic leukaemia (CLL)‐directed therapy on diffuse large B‐cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort

British Journal of Haematology, EarlyView.
Summary Diffuse large B‐cell lymphoma (DLBCL) type Richter transformation (DLBCL‐RT) in patients with chronic lymphocytic leukaemia (CLL) has a worse prognosis compared to de novo DLBCL (dnDLBCL). We investigated outcomes of patients with DLBCL‐RT with or without previous CLL‐directed therapy compared to dnDLBCL between 2002 and 2022.
Andreas Katsimigas, Mikkel Werling, Casper M. Frederiksen, Noomi Vainer, Klaus Rostgaard, Yasmin Ben‐Dali, Mariam H. Hleuhel, Christian Brieghel, Carsten U. Niemann, Caspar da Cunha‐Bang   +9 more
wiley   +1 more source

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report. [PDF]

Front Immunol
Yasuda A, Saito-Sasaki N, Kawamoto H, Sawada Y.   +3 more
europepmc   +1 more source

Primary Cutaneous Diffuse Large B-cell Lymphoma Presenting as a Non-healing Axillary Ulcer. [PDF]

Cureus
Munnangi V, John L, Cunnigaiper N.
europepmc   +1 more source

Diffuse Large B-Cell Lymphoma Presenting in a Background of Rosai-Dorfman Disease. [PDF]

Case Rep Hematol
Wu C, Meyer A, Tun AM.
europepmc   +1 more source

Concurrent Howell–Jolly body‐like inclusions, Barr bodies and Döhle bodies in an immunosuppressed patient with sepsis

British Journal of Haematology, EarlyView.
Vandana Panakkal, Nana P. Matsumoto
wiley   +1 more source

Real‐world prevalence and prognostic significance of hepatotoxicity after chimeric antigen receptor T‐cell therapy

British Journal of Haematology, EarlyView.
In this real‐world cohort of 231 patients receiving chimeric antigen receptor (CAR) T‐cell therapy, hepatotoxicity occurred in 58% of patients, predominantly as transient transaminase elevations, and was not associated with impaired 12‐month overall survival (adjusted hazard ratio [HR] 1.18, 95% confidence interval [CI] 0.71–1.94).
Julius Hollnberger, Tim Richardson, Philipp Gödel, Joshua Leutiger, Jan Christoph Schumacher, Sophie Schiestel, Benedict Allhoff, Christof Scheid, Udo Holtick, Christoph Neumann‐Haefelin, Gabriel Allo, Philipp Kasper   +11 more
wiley   +1 more source